Reported Saturday, Prelude Therapeutics Presents ASH 2025 Data Highlighting PRT12396 JAK2V617F-Selective JH2 Inhibitor And mCALR-Targeted CDK9 Degrader Antibody Conjugate In MPNs

Benzinga · 2d ago
  • First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms
  • PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026
  • First disclosure of a mutant calreticulin (mCALR) targeted degrader antibody conjugate (DAC) with a novel CDK9 degrader payload
  • JAK2V617F and mCALR are the two primary driver mutations responsible for disease progression and poor prognosis in the majority of MPN patients